Publications by authors named "Matteo Clavarezza"

Claim this Profile
E
Efficacy and toxicity of low-doses versus standard-dose enzalutamide in advanced prostate cancer. a real-world study with implications for cancer prevention/interception.
Martino Oliva, Monica Boitano, Alessio Carbone, Irene Maria Briata, Tania Buttiron Webber, Matteo Clavarezza

BMC Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Colorectal cancer-infiltrating NK cell landscape analysis unravels tissue-resident PD-1 NK cells in microsatellite instability tumors.
Valentina Obino, Chiara Giordano, Simona Carlomagno, Chiara Setti, Marco Greppi, Matteo Clavarezza

Front Immunol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Distress, Anxiety, and Depressive Symptoms on SARS-CoV-2 mRNA BNT162b2 Vaccine Efficacy in Cancer Patients.
Gabriella Rondanina, Tania Buttiron Webber, Oriana D'Ecclesiis, Marco Musso, Irene Maria Briata, Matteo Clavarezza

Cancers (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-induced thrombocytopenia in a patient with colorectal cancer: A case report.
Stefano Pasquariello, Matteo Clavarezza, Sabrina Piredda, Luca Foppiani, Giampaola Pesce

Oncol Lett· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials.
Alessandra Boccaccino, Daniele Rossini, Alessandra Raimondi, Martina Carullo, Sara Lonardi, Matteo Clavarezza

Eur J Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision fluoropyrimidines dosing in a compound heterozygous variant carrier of the DPYD gene: a case report.
Giammarco Baiardi, Matteo Clavarezza, Manuela Stella, Stefania Casazza, Andrea De Censi

Cancer Chemother Pharmacol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial.
Alessandra Raimondi, Giovanni Randon, Michele Prisciandaro, Filippo Pagani, Sara Lonardi, Matteo Clavarezza

Int J Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.
Giovanni Fucà, Alessandra Raimondi, Michele Prisciandaro, Sara Lonardi, Chiara Cremolini, Matteo Clavarezza

Oncologist· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment.
Tania Buttiron Webber, Nicoletta Provinciali, Marco Musso, Martina Ugolini, Monica Boitano, Matteo Clavarezza

Eur J Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient- versus physician-reported outcomes in a low-dose tamoxifen trial in noninvasive breast cancer.
Tania Buttiron Webber, Domenico Marra, Matteo Puntoni, Silvia Giuliano, Irene Maria Briata, Matteo Clavarezza

Breast J· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Home Se-Cure: A Home Care Service for Cancer Patients during the COVID-19 Pandemic.
Tania Buttiron Webber, Silvia Giuliano, Carlotta Patrone, Irene Maria Briata, Maria Franconeri, Matteo Clavarezza

Int J Environ Res Public Health· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study.
Roberto Moretto, Mirella Giordano, Anello M Poma, Alessandro Passardi, Alessandra Boccaccino, Matteo Clavarezza

Eur J Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study.
Alessandra Raimondi, Salvatore Corallo, Sara Lonardi, Carlotta Antoniotti, Lorenza Rimassa, Matteo Clavarezza

Support Care Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer.
Paolo Manca, Salvatore Corallo, Adele Busico, Sara Lonardi, Francesca Corti, Matteo Clavarezza

Clin Cancer Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.
Paolo Manca, Salvatore Corallo, Giovanni Randon, Sara Lonardi, Chiara Cremolini, Matteo Clavarezza

Eur J Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.
Alessandra Raimondi, Massimo Di Maio, Federica Morano, Salvatore Corallo, Sara Lonardi, Matteo Clavarezza

Eur J Cancer· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini, Sara Lonardi, Fotios Loupakis, Matteo Clavarezza

Lancet Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.
Federica Morano, Salvatore Corallo, Sara Lonardi, Alessandra Raimondi, Chiara Cremolini, Matteo Clavarezza

J Clin Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Filippo Pietrantonio, Federica Morano, Salvatore Corallo, Rosalba Miceli, Sara Lonardi, Matteo Clavarezza

JAMA Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.
Marilena Petrera, Laura Paleari, Matteo Clavarezza, Matteo Puntoni, Silvia Caviglia

BMC Cancer· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study.
Alba A Brandes, Gaetano Finocchiaro, Vittorina Zagonel, Michele Reni, Alessandra Fabi, Matteo Clavarezza

Oncotarget· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer.
Sara Campora, Eleonora Campazzi, Silvia Zanardi, Matteo Puntoni, Marco Piccininno, Matteo Clavarezza

Transl Oncol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
Alba A Brandes, Gaetano Finocchiaro, Vittorina Zagonel, Michele Reni, Claudia Caserta, Matteo Clavarezza

Neuro Oncol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.
Matteo Clavarezza, Matteo Puntoni, Alessandra Gennari, Laura Paleari, Nicoletta Provinciali

Clin Cancer Res· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial.
Matteo Lambertini, Paolo Bruzzi, Francesca Poggio, Simona Pastorino, Giovanni Gardin, Matteo Clavarezza

Support Care Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis